INTRODUCTION
============

Post-surgical pain, a major complication of general surgery, has an incidence of 41-86%\[[@b1-yujm-2018-35-1-40]\]. Adequate management of acute postoperative pain might increase patient satisfaction and reduce the risk of progression to chronic pain and associated comorbidities \[[@b2-yujm-2018-35-1-40]\]. Specifically, control of neuropathic pain as well as inflammatory pain is considered crucial for preventing chronic postoperative pain.

Pregabalin is effective in treating neuropathic pain \[[@b3-yujm-2018-35-1-40]\]. Recently, pregabalin has been studied as a single or multimodal analgesic drug for postoperative pain management in different surgeries \[[@b4-yujm-2018-35-1-40],[@b5-yujm-2018-35-1-40]\]. A decrease in pain scores, superior postoperative analgesia, and opioid sparing effects have been observed during the perioperative period after preemptive and preventive analgesia using pregabalin \[[@b5-yujm-2018-35-1-40],[@b6-yujm-2018-35-1-40]\]. However, sedation-related problems and postoperative confusion may be attributable to side effects of pregabalin \[[@b7-yujm-2018-35-1-40]\].

We evaluated the effect of pregabalin (150mg) on post-gastrectomy pain scores, total consumption of fentanyl in patient-controlled analgesia (PCA), the proportion of patients requiring rescue analgesics, and pregabalin-related side effects in patients undergoing gastrectomy under general anesthesia.

MATERIALS AND METHODS
=====================

After approval by an institutional ethics committee, written informed consent was obtained from patients. Forty-four patients aged 20-65 years, with American Society of Anesthesiologists (ASA) physical status classifications of I or II, and scheduled for open gastrectomy under general anesthesia were enrolled. Exclusion criteria included the following: (1) history of allergy to pregabalin, (2) ASA physical status of III or higher, (3) history of chronic pain or regularly receiving analgesics, (4) pregnancy or breastfeeding, and (5) history of alcohol or drug abuse.

The patients were categorized into two groups through computer-generated randomization. The pregabalin group (group P, n=20) received 150mg of pregabalin orally 2 h before anesthetic induction. The control group (group C, n=20) received placebo tablets at the same time as group P. No other pre-anesthetic medications were administered. Upon arrival at the operating room, standard monitoring involving electrocardiography, pulse oximetry, non-invasive blood pressure monitoring, and bispectral index measurement, was performed. Anesthesia was induced intravenously using 1.5-2.5 mg/kg of propofol. Target-controlled infusion of 3-4 ng/mL of remifentanil and subsequently 0.6-1mg/kg of rocuronium were administered, followed by tracheal intubation. Anesthesia was maintained using sevoflurane and remifentanil in 50% oxygen with air, maintaining both hemodynamic stability (within 20% of the preoperative baseline values of mean blood pressure) and a bispectral index of 40-60. All patients received 30mg of ketorolac intravenously for postoperative pain and 0.3mg of ramosetron, a prophylactic antiemetic, during skin closure. Sevoflurane and remifentanil were stopped at the end of surgery, and the intraoperative total infusion dose of remifentanil was recorded. Residual neuromuscular paralysis was treated with intravenous administration of 0.2 mg/kg of pyridostigmine and 0.01mg/kg of glycopyrrolate.

In post-anesthesia care, fentanyl-based intravenous PCA (fentanyl at 30 μg/kg with a total volume of 60mL) was administered. The PCA device was programmed to deliver the drug at a basal infusion rate of 0.5mL/h, with a demand of 0.5mL with a lock-out period of 15min. All study medications and PCA devices were handled by an anesthesiologist blinded to group allocation. The postoperative pain intensity was evaluated using the visual analog scale (VAS; 0: no pain, 10: worst possible pain) at different postoperative time points (30min, 2 h, 4 h, and 24 h). Rescue analgesics (50 μg of fentanyl) were administered when the VAS score exceeded 4 or upon patient request. A rescue antiemetic (10mg of metoclopramide) was injected when any emetic episode developed or upon patient request. The total consumption of fentanyl in PCA, proportion of patients requiring rescue analgesics, and pregabalin-related side effects (e.g., dizziness, sedation, and dry mouth) were also noted during the 24 h postoperative period.

On the basis of preliminary studies, the effect size of consumption of fentanyl in PCA was 0.91. The sample size per group was determined to be 20 patients with α=0.05 and a power of 0.8 using G power. Considering the dropout rate, 44 patients were needed. Data are expressed as the mean±standard deviation or number (%). IBM SPSS version 23.0 (IBM Co., Armonk, NY, USA) was used for analysis and the Student t test, chi-squared test, and Fisher exact test were used. A *p*-value \<0.05 was considered statistically significant.

RESULTS
=======

A total of 44 patients were randomized, and the final analysis included data from 40 patients. Four patients were excluded because two underwent re-gastrectomy, one refused to participate, and one did not understand the VAS instrument. No statistical differences were observed in the demographic characteristics of patients or in the operative data, including intraoperative remifentanil consumption ([Table 1](#t1-yujm-2018-35-1-40){ref-type="table"}). The postoperative pain intensity obtained from VAS scores did not exhibit significant differences at any postoperative time point (30min, 2 h, 4 h, and 24 h; [Fig. 1](#f1-yujm-2018-35-1-40){ref-type="fig"}). Consumption of fentanyl in PCA and the proportion of patients who required rescue analgesics at different time intervals (0-2 h, 2-4 h, and 4-24 h) did not differ significantly between the groups during the 24 h postoperative period ([Table 2](#t2-yujm-2018-35-1-40){ref-type="table"}, [3](#t3-yujm-2018-35-1-40){ref-type="table"}). The groups did not differ in terms of the occurrence of dizziness, sedation, pruritus, and dry mouth ([Table 4](#t4-yujm-2018-35-1-40){ref-type="table"}).

DISCUSSION
==========

This study revealed that preoperative pregabalin (150mg) exerted no effect on intraoperative remifentanil consumption, post-surgical pain, or consumption of fentanyl in PCA within 24 h of gastrectomy. Pregabalin-related adverse effects, such as dizziness, sedation, and dry mouth, did not differ between the two groups.

A nociceptive stimulus caused by tissue injury during surgery releases multiple inflammatory mediators and neurotransmitters, which leads to peripheral sensitization, and subsequently produces central sensitization through afferent input to the central nervous system\[[@b8-yujm-2018-35-1-40]\]. Although the mechanisms underlying progression from acute to chronic pain is not completely understood, controlling acute postoperative pain is critical because it poses a risk of chronic pain \[[@b9-yujm-2018-35-1-40]\]. Acute postoperative pain is recognized to have early inflammatory and late neuropathic constituents \[[@b10-yujm-2018-35-1-40]\]; therefore, preventing chronic pain involves not only alleviating inflammatory pain but also addressing neuropathic pain. On the basis of the pathophysiology of acute postoperative pain, using a single drug or intervention would not be sufficient as an effective treatment, particularly for moderate to severe pain.

Multimodal approaches to pain management have been demonstrated in many studies, with superior postoperative analgesia with fewer side effects than a single analgesic. Broadly, multimodal approaches for resolving pain involved pharmacological and non-pharmacological components; in addition, opioids, non-steroidal anti-inflammatory drugs, gabapentinoids, ketamine, dexmedetomidine, local anesthetics, regional anesthesia, and transcutaneous electrical nerve stimulation have been used in multimodal analgesic regimens \[[@b11-yujm-2018-35-1-40]-[@b15-yujm-2018-35-1-40]\]. Kehlet and Dahl demonstrated the effect of multimodal regimens in postoperative pain, and this approach, by combining medications with different mechanisms, achieved superior analgesia and fewer side effects \[[@b16-yujm-2018-35-1-40]\].

Pregabalin has been extensively evaluated as part of multimodal regimens for pain. Pregabalin binds to calcium channels and subsequently modulates calcium influx and several excitatory neurotransmitters \[[@b17-yujm-2018-35-1-40]\]. This mode of action can confer antiepileptic, anxiolytic, and analgesic effects. Moreover, the rapid absorption and linear pharmacokinetics of pregabalin after oral administration allow it to be used as a preemptive adjuvant as well as an acute postoperative analgesic during the perioperative period \[[@b18-yujm-2018-35-1-40]\]. Many studies have examined the utility of pregabalin in post-surgical pain. Agarwal et al. reported that preoperative pregabalin reduced post-surgical pain and fentanyl requirement in patients undergoing laparoscopic cholecystectomy \[[@b19-yujm-2018-35-1-40]\]. In a study by Rajappa et al., preoperative administration of 150mg of pregabalin was optimal for alleviating acute post-mastectomy morphine consumption \[[@b4-yujm-2018-35-1-40]\]. However, some studies have failed to demonstrate analgesic benefits of pregabalin during the perioperative period. Jokera et al. reported no analgesic effect of preoperative use of pregabalin after laparoscopic hysterectomy \[[@b20-yujm-2018-35-1-40]\]. Furthermore, Paech et al. did not observe stronger pain relief in patients administered pregabalin preoperatively \[[@b21-yujm-2018-35-1-40]\]. In this study, we found no effect of 150mg of pregabalin on post-surgical pain or attenuation of fentanyl consumption in patients undergoing gastrectomy. These conflicting results concerning the utility of pregabalin could be due to differences in the dosage and regimen, severity of pain, and type of surgery.

We selected a single dose of pregabalin to identify any beneficial effect on post-gastrectomy pain. In pregabalin medication instructions, 150mg of pregabalin is suggested as the starting dose for treating neuropathic pain \[[@b17-yujm-2018-35-1-40]\]. In the study of Esmat et al., both 150 and 300mg of pregabalin exerted similar analgesic effects on postoperative pain after laparoscopic cholecystectomy, but 300mg of pregabalin resulted in more side effects \[[@b22-yujm-2018-35-1-40]\]. In the present study, we did not find any analgesic effects of 150mg of pregabalin on post-gastrectomy pain. These results might be due to the subtherapeutic doses of pregabalin used for the surgical population in our study. The larger doses on the occurrence of side effects should be cautiously examined.

This study had some limitations. First, we evaluated only a single dose of pregabalin. A study on different doses of pregabalin might be required to determine the benefits in postgastrectomy patients. Second, although power analysis was performed, the sample size was relatively small; additional studies with a larger sample size may reduce the risk of type II error.

In conclusion, preoperative administration of 150mg of pregabalin does not reduce postoperative pain or fentanyl consumption in the 24 h post-gastrectomy period.
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###### 

Patient characteristics

  Characteristic                  Patients group   
  ------------------------------- ---------------- ---------------
  Age (yr)                        53.2±7.4         54.2±7.8
  Sex (M/F)                       12/8             14/6
  Weight (kg)                     66.2±7.9         64.7±9.2
  Height (cm)                     163.0±6.4        164.8±7.0
  STG/TG                          17/3             14/6
  Duration of surgery (min)       172.1±19.5       170.0±26.2
  Duration of anesthesia (min)    194.2±19.4       195.0±25.0
  Remifentanil consumption (μg)   1,210.0±292.6    1,197.5±208.2

Values are presented as either mean±standard deviation or number.

Group C, control group; Group P, pregabalin group; STG, subtotal gastrectomy; TG, total gastrectomy.

###### 

PCA fentanyl consumption and patients who required rescue analgesics

           Patients group   
  -------- ---------------- ------------
  0-2 h    70.5±24.6        75.7±21.9
  2-4 h    58.5±21.6        68.2±25.3
  4-24 h   580.5±80.6       619.5±79.6
  0-24 h   709.5±107.3      763.5±82.5

Values are presented as either mean±standard deviation.

PCA, patient controlled analgesia; group C, control group; group P, pregabalin group.

###### 

Proportion of patients who required rescue analgesics

               Patients group   
  ------------ ---------------- ---------
  30 min       17 (85)          17 (85)
  30 min-2 h   12 (60)          11 (55)
  2-4 h        9 (45)           8 (40)
  4-24 h       4 (20)           3 (15)

Values are presented as number (%).

Group C, control group; group P, pregabalin group.

###### 

Postoperative adverse events

              Patients group   
  ----------- ---------------- ---
  Vomiting    1                1
  Sedation    0                1
  Dizziness   1                1
  Dry mouth   1                1
  Pruritis    0                1

Values are presented as number.

Group C, control group; group P, pregabalin group.
